HYDRADERMA Trademark

Trademark Overview

On Wednesday, March 2, 2022, a trademark application was filed for HYDRADERMA with the United States Patent and Trademark Office. The USPTO has given the HYDRADERMA trademark a serial number of 97291998. The federal status of this trademark filing is SUSPENSION INQUIRY - MAILED as of Friday, October 11, 2024. This trademark is owned by Prollenium Medical Technologies, Inc.. The HYDRADERMA trademark is filed in the Medical Instrument Products category with the following description:

Stamp comprising a plurality of injection needles for delivery of drugs, nutrients and biological compounds to the hair and skin; roller comprising a plurality of injection needles for delivery of drugs, nutrients and biological compounds to the hair and skin
hydraderma

General Information

Serial Number97291998
Word MarkHYDRADERMA
Filing DateWednesday, March 2, 2022
Status651 - SUSPENSION INQUIRY - MAILED
Status DateFriday, October 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Pseudo MarkHYDRA DERMA
Goods and ServicesStamp comprising a plurality of injection needles for delivery of drugs, nutrients and biological compounds to the hair and skin; roller comprising a plurality of injection needles for delivery of drugs, nutrients and biological compounds to the hair and skin

Classification Information

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateMonday, March 7, 2022
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameProllenium Medical Technologies, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRichmond Hill, Ontario L4B1A3
CA

Trademark Events

Event DateEvent Description
Wednesday, October 26, 2022SUSPENSION LETTER WRITTEN
Saturday, March 5, 2022NEW APPLICATION ENTERED
Monday, March 7, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, October 22, 2022ASSIGNED TO EXAMINER
Wednesday, October 26, 2022LETTER OF SUSPENSION E-MAILED
Wednesday, October 26, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, April 26, 2023SUSPENSION INQUIRY WRITTEN
Wednesday, April 26, 2023INQUIRY TO SUSPENSION E-MAILED
Wednesday, April 26, 2023NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, May 8, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, September 27, 2023ASSIGNED TO LIE
Wednesday, September 27, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, September 27, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, November 17, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, October 25, 2023NON-FINAL ACTION WRITTEN
Wednesday, October 25, 2023NON-FINAL ACTION E-MAILED
Wednesday, October 25, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 17, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, November 17, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, November 17, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, November 17, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, November 21, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, November 21, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 22, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, November 25, 2023SUSPENSION LETTER WRITTEN
Saturday, November 25, 2023LETTER OF SUSPENSION E-MAILED
Saturday, November 25, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, October 11, 2024NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Wednesday, October 16, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Friday, October 11, 2024INQUIRY TO SUSPENSION E-MAILED
Friday, October 11, 2024SUSPENSION INQUIRY WRITTEN

Related Keywords

hydraderma biological compounds hair skin nutrients drugs comprising plurality injection delivery